Caleo Biotechnologies
Caleo Biotechnologies develops advanced human tissue models to enable more predictive and clinically relevant preclinical research, with a focus on fibrotic and inflammatory diseases. Their core platform integrates epithelial, immune, and mesenchymal/stromal compartments into self-organizing, patient-derived 3D tissue models. These models are used to study disease mechanisms, evaluate drug responses, and de-risk therapy development by capturing patient-specific biology and microenvironmental interactions. Caleo also combines these systems with molecular analysis and scalable, AI-driven analytics to support drug discovery and translational research.
Industries
N/A
Products
A system for generating self-organizing, multicellular human tissue constructs, including epithelial, immune, and stromal compartments, for disease modeling and drug testing.
A system for generating self-organizing, multicellular human tissue constructs, including epithelial, immune, and stromal compartments, for disease modeling and drug testing.
Expertise Areas
- Preclinical disease modeling
- Tissue engineering
- Human-relevant translational research
- Fibrosis and inflammatory disease research
Key Technologies
- 3D tissue culture
- Single nucleus RNA sequencing
- Immunohistochemistry
- AI-driven analytics
News & Updates
Article discussing the limitations of current fibrosis models and showing how advanced tissue models enable the study of dynamic multicellular interactions driving disease.
Describes the preservation of immune, stromal, and epithelial components in ex vivo tissue models, supporting high-resolution studies of inflammation and fibrosis.
Demonstrates that transplanted tissue models retain phenotypic and functional characteristics of the original patient tissue.
Outlines the critical need for predictive, clinically relevant preclinical models to improve drug discovery outcomes.
Article discussing the limitations of current fibrosis models and showing how advanced tissue models enable the study of dynamic multicellular interactions driving disease.
Describes the preservation of immune, stromal, and epithelial components in ex vivo tissue models, supporting high-resolution studies of inflammation and fibrosis.
Demonstrates that transplanted tissue models retain phenotypic and functional characteristics of the original patient tissue.
Outlines the critical need for predictive, clinically relevant preclinical models to improve drug discovery outcomes.